Medincell Sa Stock Operating Margin
| MDCLF Stock | USD 34.39 27.41 392.69% |
As of the 29th of January, MedinCell secures the Standard Deviation of 50.28, mean deviation of 12.66, and Risk Adjusted Performance of 0.1028. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MedinCell SA, as well as the relationship between them. Please verify MedinCell SA mean deviation, variance, as well as the relationship between the Variance and maximum drawdown to decide if MedinCell SA is priced some-what accurately, providing market reflects its recent price of 34.39 per share. Given that MedinCell SA has variance of 2528.0, we recommend you to check MedinCell's last-minute market performance to make sure the company can sustain itself at a future point.
MedinCell's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing MedinCell's valuation are provided below:MedinCell SA does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. MedinCell |
MedinCell 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to MedinCell's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of MedinCell.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in MedinCell on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding MedinCell SA or generate 0.0% return on investment in MedinCell over 90 days. MedinCell is related to or competes with BioInvent International, Avacta Group, Healios KK, PureTech Health, GenSight Biologics, Northwest Biotherapeutics, and Verano Holdings. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers an... More
MedinCell Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure MedinCell's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess MedinCell SA upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1268 | |||
| Maximum Drawdown | 392.69 |
MedinCell Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for MedinCell's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as MedinCell's standard deviation. In reality, there are many statistical measures that can use MedinCell historical prices to predict the future MedinCell's volatility.| Risk Adjusted Performance | 0.1028 | |||
| Jensen Alpha | 6.59 | |||
| Total Risk Alpha | 2.87 | |||
| Treynor Ratio | (2.02) |
MedinCell January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1028 | |||
| Market Risk Adjusted Performance | (2.01) | |||
| Mean Deviation | 12.66 | |||
| Coefficient Of Variation | 781.02 | |||
| Standard Deviation | 50.28 | |||
| Variance | 2528.0 | |||
| Information Ratio | 0.1268 | |||
| Jensen Alpha | 6.59 | |||
| Total Risk Alpha | 2.87 | |||
| Treynor Ratio | (2.02) | |||
| Maximum Drawdown | 392.69 | |||
| Skewness | 7.81 | |||
| Kurtosis | 61.0 |
MedinCell SA Backtested Returns
MedinCell is out of control given 3 months investment horizon. MedinCell SA has Sharpe Ratio of 0.13, which conveys that the firm had a 0.13 % return per unit of risk over the last 3 months. We were able to break down and interpolate twenty different technical indicators, which can help you to evaluate if expected returns of 6.44% are justified by taking the suggested risk. Use MedinCell SA Standard Deviation of 50.28, risk adjusted performance of 0.1028, and Mean Deviation of 12.66 to evaluate company specific risk that cannot be diversified away. MedinCell holds a performance score of 10 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -3.17, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning MedinCell are expected to decrease by larger amounts. On the other hand, during market turmoil, MedinCell is expected to outperform it. Use MedinCell SA variance, daily balance of power, relative strength index, as well as the relationship between the total risk alpha and day typical price , to analyze future returns on MedinCell SA.
Auto-correlation | 0.00 |
No correlation between past and present
MedinCell SA has no correlation between past and present. Overlapping area represents the amount of predictability between MedinCell time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of MedinCell SA price movement. The serial correlation of 0.0 indicates that just 0.0% of current MedinCell price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 101.63 |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, MedinCell SA has an Operating Margin of -3.2526%. This is 90.73% lower than that of the Healthcare sector and 97.1% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 40.97% lower than that of the firm.
MedinCell Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MedinCell's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of MedinCell could also be used in its relative valuation, which is a method of valuing MedinCell by comparing valuation metrics of similar companies.MedinCell is currently under evaluation in operating margin category among its peers.
MedinCell Fundamentals
| Return On Asset | -0.4 | |||
| Operating Margin | (3.25) % | |||
| Current Valuation | 190.33 M | |||
| Shares Outstanding | 25.22 M | |||
| Shares Owned By Insiders | 47.61 % | |||
| Shares Owned By Institutions | 19.00 % | |||
| Price To Book | 34.52 X | |||
| Price To Sales | 31.58 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 4.09 M | |||
| EBITDA | (21.45 M) | |||
| Net Income | (24.81 M) | |||
| Cash And Equivalents | 34.39 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 16.25 M | |||
| Debt To Equity | 4.86 % | |||
| Current Ratio | 2.84 X | |||
| Book Value Per Share | (1.04) X | |||
| Cash Flow From Operations | (21.36 M) | |||
| Earnings Per Share | (0.88) X | |||
| Number Of Employees | 151 | |||
| Beta | 1.02 | |||
| Market Capitalization | 244.65 M | |||
| Total Asset | 44.3 M | |||
| Z Score | 9.0 | |||
| Net Asset | 44.3 M |
About MedinCell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MedinCell SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedinCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedinCell SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in MedinCell Pink Sheet
MedinCell financial ratios help investors to determine whether MedinCell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedinCell with respect to the benefits of owning MedinCell security.